(3-氟苯基)-吡啶-3-基甲酮 | 79568-07-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (3-氟苯基)-吡啶-3-基甲酮
• 英文名称: (3-fluorophenyl)(pyridin-3-yl)methanone
• 英文别名: 3-(3-fluorobenzoyl)pyridine；(3-fluorophenyl)-pyridin-3-ylmethanone
• CAS: 79568-07-3
• 化学式: C₁₂H₈FNO
• 分子量: 201.2
• InChiKey: IEVCOTJIGFKWIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  (3-氟苯基)-吡啶-3-基甲酮 在 盐酸 、 汞 、 锌 作用下， 反应 30.0h， 以29%的产率得到3-(3-fluorobenzyl)pyridine
  参考文献：
  名称：

  Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine .beta.-hydroxylase. 4. Structure-activity relationships at the copper binding site

  摘要：

  Structure-activity relationships (SAR) were determined for novel multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1) by examining the effects upon in vitro inhibitory potencies resulting from structural changes at the copper-binding region of inhibitor. Attempts were made to determine replacement groups for the thione sulfur atom of the prototypical inhibitor 1-(4-hydroxybenzyl)imidazole-2-thione described previously. The synthesis and evaluation of oxygen and nitrogen analogues of the soft thione group demonstrated the sulfur atom to be necessary for optimal activity. An additional series of imidazole-2-thione relatives was prepared in an effort to probe the relationship between the pKa of the ligand group and inhibitory potency. In vitro inhibitory potency was shown not to correlate with ligand pKa over a range of approximately 10 pKa units, and a rationale for this is advanced. Additional ligand modifications were prepared in order to explore bulk tolerance at the enzyme oxygen binding site and to determine the effects of substituting a six-membered ligand group for the five-membered imidazole-2-thione ligand.

  DOI：

  10.1021/jm00164a051
• 作为产物：
  描述：

  3-nitrophenyl 3-pyridyl ketone 在 盐酸 、 tetrafluoroboric acid 、 tin(ll) chloride 、 sodium nitrite 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.75h， 生成 (3-氟苯基)-吡啶-3-基甲酮
  参考文献：
  名称：

  与齐美啶有关的吡啶基烯丙基胺的合成及其对神经元单胺摄取的抑制作用。

  摘要：

  抗抑郁药齐美碱[6，（Z）-3-（4-溴苯基）-N，N-二甲基-3-（3-吡啶基）烯丙胺]的类似物是神经元5-羟色胺再摄取的选择性抑制剂，其合成方法如下：为了获得具有顺式构型（相对于吡啶基和烯丙胺）的化合物的几种途径。两种方法利用适当取代的苯甲酰基吡啶作为起始原料。在另外两个途径中，将6中的溴直接置换（CN）或通过相应的硫代衍生物转化为H，Cl，I，Me，SiMe3和SMe。通过UV，1H NMR和镧系元素引起的1H NMR位移确定构型。通过测量小鼠脑切片（体外和体内）中的[3H]去甲肾上腺素和5-羟基[14C]色胺的积累，将这些化合物评估为摄取抑制剂。在顺式系列中，对位取代有利于5-羟基色胺活性，而邻位取代有利于NA活性。对5-羟色胺的体外作用对对位取代基的变化不敏感，而仅用Cl，Br（6）和I观察到明显的体内作用。

  DOI：

  10.1021/jm00144a025

文献信息

• METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt
  申请人：Janssen Pharmaceutica NV

  公开号：US20150105366A1

  公开（公告）日：2015-04-16

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明包括式I的化合物。 其中： R1、R2、R3、R4、R5、R6、R7、R8和R9在说明书中定义。 本发明还包括治疗或改善综合征、紊乱或疾病的方法，其中所述综合征、紊乱或疾病为类风湿性关节炎或银屑病。本发明还包括通过给予治疗有效量的至少一个权利要求1的化合物，来调节哺乳动物中RORγt活性的方法。
• [EN] METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T<br/>[FR] MODULATEURS QUINOLINYLE À LIAISON MÉTHYLÈNE DE ROR-GAMMA-T
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015057205A1

  公开（公告）日：2015-04-23

  The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明包括公式(I)的化合物。其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在说明书中定义。本发明还包括治疗或改善综合症、障碍或疾病的方法，其中所述综合症、障碍或疾病为类风湿性关节炎或银屑病。本发明还包括通过管理一个治疗有效量的至少一个权利要求1的化合物来调节哺乳动物中的RORγt活性的方法。
• 3-aralkyl-2-mercaptoyridines as dopamine-.beta.-hydroxylase inhibitors
  申请人：SmithKline Beckman Corporation

  公开号：US04839371A1

  公开（公告）日：1989-06-13

  Disclosed are novel substituted 3-aralkyl-2-mercaptopyridines of the structure: ##STR1## processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy in particular as dopamine-.beta.-hydroxylase inhibitors.

  揭示了新颖的结构为3-芳基基-2-巯基吡啶的取代物，其制备方法，制备中有用的中间体，含有它们的药物组合物以及它们在特定治疗中的用途，尤其是作为多巴胺-β-羟化酶抑制剂。
• Acid- or base-promoted photostimulated homolytic tert-butylation of pyridines and thiophenes
  作者：Byeong Hyo Kim、Insik Jeon、Tae Hee Han、Hae Jin Park、Young Moo Jun

  DOI：10.1039/b104906m

  日期：——

  Regioselective photostimulated homolytic tert-butylations for heteroaromatics such as pyridines or thiophenes are investigated with tert-butylmercury(II) chloride in the presence of toluene-p-sulfonic acid (PTSA) or 1,4-diazabicyclo[2.2.2]octane (DABCO) respectively. While the promotion effect of acid is quite strong for basic pyridines, the acid does not promote the reaction effectively for non-basic

  区域选择性光刺激的均相叔丁基化用于杂芳族化合物，例如吡啶类 或者 噻吩 被调查 叔-butylmercury（II），氯化 在......的存在下 甲苯-对磺酸 （PTSA）或 1,4-二氮杂双环[2.2.2]辛烷（DABCO）。虽然酸对碱性的促进作用很强吡啶类，对于非碱性酸不能有效地促进反应 噻吩。另一方面，吡啶类 和 噻吩碱促进的均质叔丁基化反应具有相似的趋势，反应性主要受取代基控制羰 或氰基以及区域选择性。
• Methylene linked quinolinyl modulators of RORγt
  申请人：Janssen Pharmaceutica NV

  公开号：US09284308B2

  公开（公告）日：2016-03-15

  The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明涉及式I的化合物，其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在规范中定义。本发明还涉及一种治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病为风湿性关节炎或银屑病。本发明还涉及一种通过给哺乳动物施用至少一种权利要求1的化合物的治疗有效量来调节RORγt活性的方法。